Healthcare Research Reports-Pharma Proff

Want to Have A More Appealing Juvenile Myelomonocytic Leukemia Therapeutics Pipeline Analysis?

2019-07-18T03:18:00.000-07:00

Juvenile myelomonocytic leukemia is a rare disease that occurs mostly in the children who are under four years of age. The abnormal growth of the monocytes results in the accumulation of monocytes in the bone marrow.

This leads to improper functioning of the bone marrow. The actual cause of juvenile myelomonocytic leukemia is still unknown; however, mutation in the RAS gene is observed in patients with the disease. Fatigue, weakness, dry cough, pallor, and fever are major symptoms of the medical condition.

Get the detailed analysis @ https://www.pharmaproff.com/report/juvenile-myelomonocytic-leukemia-therapeutics-pipeline-analysis

The University of Minnesota is in the process of developing stem cell therapy for the treatment of juvenile myelomonocytic leukemia. Celgene Corporation is also developing azacytidine, a DNA methylation inhibitor, for the treatment of this medical condition.

· The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

· Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:

Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Prostatitis Therapeutics Pipeline to Witness Remarkable Growth due to Increased Number of Pipeline Candidates by Drug Developers

2019-07-11T04:23:00.000-07:00

Prostatitis refers to a group of disorders that lead to inflammatory condition causing pain in prostate gland. The disease is categorized into four forms: chronic pelvic pain syndrome (CPPS), acute bacterial prostatitis, chronic bacterial prostatitis, and asymptomatic prostatitis. CPPS, also called prostatodynia is the occurrence of prostatitis symptoms, without inflammation or bacterial infections. Acute bacterial prostatitis is described as inflammation of the prostate gland caused by bacteria such as Escherichia coli and Klebsiella. Chronic bacterial prostatitis is the recurrent infection and inflammation of the prostate and urinary tract, and asymptomatic prostatitis is an uncommon type wherein the patient experiences an inflamed prostate without any bacterial infection.

Download the sample report at: https://www.pharmaproff.com/request-sample/1239

The chronic pelvic pain syndrome leads to pain in penis, lower back, scrotum, central lower abdomen, and between scrotum and anus, acute bacterial prostatitis and chronic bacterial prostatitis tend to change urinary frequency, fever, chills, burning sensation during urination, urinary blockage, nausea, and vomiting, whereas patients with asymptomatic prostatitis do not have symptoms of prostatitis.

The occurrence of prostatitis can be diagnosed by a physical examination, blood test digital rectal exam (DRE), prostate-specific antigen (PSA) blood test, and cystoscopy and urodynamic tests. Some of the commonly used treatment options include medications (antibiotics, alpha-blockers, and anti-inflammatory agents), lifestyle changes, and acupuncture.

Get the detailed analysis at: https://www.pharmaproff.com/report/prostatitis-therapeutics-pipeline
In addition, Rapaflo (Kissei Pharmaceutical Co. Ltd.), Proscar (Merck & Co. Inc.), Avodart (GlaxoSmithKline plc), and Pamelor (Mallinckrodt LLC) are some of the drugs approved by the U.S. Food and Drug Administration (USFDA) for the treatment of prostatitis.
According to the research findings, majority of the pipeline drug candidates are being developed for oral administration. It has been observed that the oral route of medications is convenient, available in delayed or rapid release formulation, less risk of systemic infections, and inexpensive in nature, and also provides improved patient’s compliance.

Companies that are involved in developing therapeutics for prostatitis have shown positive clinical results in the various phases of drug development. For instance, in September 2018, Santen Pharmaceutical Co. Ltd. announced positive data from the phase III trial of Opsiria for the treatment of patients with prostatitis. The results of the study concluded that the treatment with Opsiria had a favorable safety and tolerability profile. The study also recorded efficacy of Opsiria in lowering down the inflammation in eyes.

Global Market of Prostatitis Therapeutics is Expected to Increase Statistically in the next 10 years

Humira (AbbVie Inc.), Geocillin (Pfizer Inc.), Floxin (Ortho-McNeil-Janssen Pharmaceuticals Inc.), and Levaquin (Janssen Pharmaceuticals Inc.) are the approved drugs for the treatment of prostatitis and with the emergence of late- and mid-stage pipeline products in the market, the overall prostatitis therapeutics market is expected to grow significantly in the upcoming years.
Aquinox Pharmaceuticals Inc., AbbVie Inc., Pfizer Inc., Kissei Pharmaceutical Co. Ltd., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Aldeyra Therapeutics Inc., Ortho-McNeil-Janssen Pharmaceuticals Inc., GlaxoSmithKline plc, Mallinckrodt LLC, and Novartis AG are some of the key players involved in the development of therapeutic drugs indicated for the treatment of prostatitis.

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of prostatitis. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the prostatitis therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in the report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to prostatitis.

Get the detailed overview of Immunoglobulin A (IgA) Nephropathy competitive landscape

2019-07-04T05:16:00.001-07:00

According to a new research report “Immunoglobulin A (IgA) Nephropathy-Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, Patient Size, and Epidemiology Forecast to 2028” published by Pharma Proff, Immunoglobulin A (IgA) Nephropathy therapeutics currently exhibits a proliferating pipeline with 24 therapeutic candidates.

Download the free sample report @ https://www.pharmaproff.com/request-sample/1211

IgA Nephropathy is referred to being as the utmost causing agent of Glomerulonephritis, which is the inflammation of the glomeruli (part of the kidney that filters blood). IgA antibodies are produced by immune system and act as first line of defense against inhaled and ingested pathogens. IgA Nephropathy is an auto immune disorder caused due to the accumulation of the immunoglobulin A (IgA) which results in inflammation and further damages the glomeruli in kidney. This damage to kidney results in presence of blood and protein in urine, and over time may progress to end-stage renal disease (ESRD).

Get the detailed analysis @ https://www.pharmaproff.com/report/iga-nephropathy-pipeline-analysis

According to research findings, majority of the drug candidates in IgA Nephropathy pipeline are undergoing Phase II trials and have shown positive results. It has been observed that subcutaneous route of administration is convenient because of more efficacy and safety; it is more adoptable because of its larger dosage, that can be transmitted subcutaneously; sustainable release of drugs is possible as the muscles can slowly release the drugs into the body. Also, according to the analysis, maximum number of drugs in the pipeline are being developed as small molecules.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1211

The epidemiology analysis in the report provides risk factors and trends of IgA Nephropathy in seven major markets (7MM, including U.S., Japan, and EU5 [which includes Germany, France, U.K., Italy, and Spain]) and gives a ten-year forecast for the prevalent and treated cases of IgA nephropathy in each of the regions in pediatric, adult, and geriatric populations. Europe is likely to have the highest number of prevalent cases of IgA Nephropathy among the 7MM throughout the period of analysis.
Some of the key players involved in the development of the drug candidates for IgA Nephropathy in the late and mid stage include Mallinckrodt plc, Calliditas Therapeutics AB., Anthera Pharmaceuticals Inc., Rigel Pharmaceuticals Inc., Merck KGaA, Retrophin Inc., and Omeros Corporation.

Tuberous Sclerosis Therapeutics Pipeline Analysis 2018

2019-05-30T06:17:00.000-07:00

Tuberous sclerosis, also known as tuberous sclerosis complex, is a genetic disorder characterized by the growth of numerous noncancerous (benign) tumors in many parts of the body.

It can occur in the brain, skin, kidneys, and other organs, in some cases leading to significant health problems. The signs and symptoms of the disease vary from person to person. Virtually all affected people have skin abnormalities, including patches of unusually light-coloured skin, areas of raised and thickened skin, and growths under the nails. It can also cause facial angiofibromas, tumors on the face beginning in childhood.

Some affected children have the characteristic features of autism, a developmental disorder that affects communication and social interaction.

Get the Research Report about Tuberous Sclerosis Therapeutics At: https://www.pharmaproff.com/request-sample/1120

The drug candidates of tuberous sclerosis disease pipeline include, but not limited to, cannabidiol, and TAK-935. Novartis AG, GW Pharmaceuticals plc and Takeda Pharmaceutical Company Limited are some of the major companies having drugs in the tuberous sclerosis therapeutics pipeline.

Postoperative Ileus Therapeutics Pipeline Analysis 2018

2019-05-23T03:26:00.001-07:00

Postoperative ileus is defined as malfunctioning of intestinal motility after major abdominal surgeries. It generally affects large number of patients who are undergoing bowel resection surgery which causes significant discomfort and extend hospital stay.

Postoperative ileus affects small intestine, stomach and large intestine. The disease is broadly categorized into primary and secondary type. The primary type is caused by surgery and concomitant opioid treatment; while, the secondary type is mainly concurrent with other precipitating factors or complications such as hematoma, or other infections.

Download the research report Postoperative Ileus Therapeutics Pipeline about at:
https://www.pharmaproff.com/request-sample/1033

It can be prevented by careful handling of tissues, minimal unnecessary adhesiolysis, laparoscopy, epidural analgesia, alternative analgesics and preoperative administration of µ-opioid receptor antagonists. RaQualia Pharma Inc., and Leading BioSciences Inc. are key players in the postoperative ileus pipeline arena. For instance, Leading BioSciences Inc. is currently developing LB1148, a serine protease inhibitor, for the treatment of postoperative ileus.

Adenosine 5-Monophosphate Activated Protein Kinase (AMPK) Modulators Therapeutics Pipeline Analysis 2018

2019-04-15T07:12:00.002-07:00

Adenosine 5-monophosphate activated protein kinase (AMPK) plays an important role in regulation of homeostasis. Dysregulation of AMPK can result in many diseases which includes obesity and type 2 diabetes. Several studies have also suggested that AMPK are also associated with the development of neurological diseases and cancer.

Download the sample report @ https://www.pharmaproff.com/request-sample/1172

Despite of many advancements in the development of anti-cancer therapies, cancer is still one of the major causes of deaths, globally. AMPK is one of the newest targets for the anti-cancer therapies, which modulates cellular protein and lipid metabolism, affecting the cellular growth and division. The importance of AMPK mediate signalling in various diseases and its complexity suggested that there is an urgent need for the development of additional AMPK modulators that can be used to not only disturb the mechanism of action but also as a drug candidate for therapeutic development. Also, researches have demonstrated that, in-depth knowledge and evidences are required to produce desired physiological outcomes by developing specific targeted therapies with reduced adverse events and better efficacy.

Get the detailed analysis @ https://www.pharmaproff.com/report/ampk-modulators-therapeutics

Esperion Therapeutics Inc. is in the process of developing Bempedoic acid as a small molecule which acts as an AMPK stimulant for the treatment of hypercholesterolemia, dyslipidaemia, and hypertension. Betagenon AB, Boehringer Ingelheim International GmbH, and Poxel SA are some other companies having pipeline AMPK modulators for the management of several diseases.

Dilated Cardiomyopathy Therapeutics- Pipeline Analysis 2018

2019-04-12T06:59:00.001-07:00

Dilated cardiomyopathy is a type of cardiovascular disease, that is characterized by left systolic dysfunction and ventricular enlargement. This condition is found to be associated with cardiac arrhythmias, congestive heart failure, and thromboembolic disease.

Download the sample report at: https://www.pharmaproff.com/request-sample/1002

Some of the symptoms associated with dilated cardiomyopathy are leg edema, shortness of breath, fainting, weight gain, palpitation, dizziness, and blood clots in the dilated left ventricle.

Get the detailed analysis at: https://www.pharmaproff.com/report/dilated-cardiomyopathy-therapeutics-pipeline-analysis

The main risk factors for the occurrence of this disease are metabolic syndrome, chronic alcoholic use, thyroid disease, and viral infection of the heart. Array BioPharma Inc. is in the process of developing ARRY-797 as a selective p38 mitogen-activated protein kinase inhibitor for the treatment of dilated cardiomyopathy.

Besides, MyoKardia Inc. is also in the process of developing MYK-491 as a cardiac myosin stimulant for the treatment of dilated cardiomyopathy. Some of the companies involved in dilated cardiomyopathy pipeline are Kasiak Research Pvt. Ltd., and Prometic Life Sciences Inc. among others.

Primary Immune Deficiency Diseases Therapeutics - Pipeline Analysis 2018, Clinical Trials & c

2019-04-09T04:51:00.001-07:00

Primary immune deficiency diseases are rare and genetic disorders, that are characterized by an impaired immune system. Some of the symptoms observed in the patients with these diseases are blood disorders, autoimmune disorders, recurrent pneumonia, inflammation of internal organs, and digestive problems.

Download the sample report @ https://www.pharmaproff.com/request-sample/1051
Primary immune deficiency diseases can occur due to B-cell deficiencies, T-cell deficiencies, defective phagocytes, combination of B- and T-cell deficiencies, and complement deficiencies.

Get the detailed analysis @ https://www.pharmaproff.com/report/primary-immune-deficiency-diseases-therapeutics-pipeline-analysis

The only risk factor associated with this disease is family history. GigaGen Inc. is in the process of developing recombinant intravenous immunoglobulin (rIVIG) for the treatment of primary immune deficiency diseases. X4 Pharmaceuticals Inc. is in the process of developing X4P-001-RD as a CXCR4 receptor antagonist for the treatment this disease. Orchard Therapeutics Ltd. is also engaged in the pipeline for this disorder.